person · Reporting owner

White William Richard

Disclosed activity across 4 companies

Tapewire entity: 27988
SEC CIK: 0001778739

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Disc Medicine, Inc.IRON · Entity 2273	Director	June 18, 2026	June 23, 2026
Yarrow Bioscience, Inc.YARW · Entity 6871	Director	July 27, 2026	July 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Disc Medicine, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17	Direct	6,212	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 6,212 · Balance 6,212 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Yarrow Bioscience, Inc.

Report date July 27, 2026 · Filed July 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.19 · Expires 2036-04-17	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-27 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer"). F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time. F3: This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").

F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.

F3: This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Akero Therapeutics, Inc.

Report date December 09, 2025 · Filed December 09, 2025

Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-12-09 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2025-12-09 · Disposition to issuer · Disposed 10,179 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-12-09 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2025-12-09 · Disposition to issuer · Disposed 47,573 · Balance 0 F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16	Direct	Reported balance After 2025-12-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-09 · Disposition to issuer · Disposed 3,421 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08	Direct	Reported balance After 2025-12-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-09 · Disposition to issuer · Disposed 5,032 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09	Direct	Reported balance After 2025-12-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-12-09 · Disposition to issuer · Disposed 2,328 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08	Direct	Reported balance After 2025-12-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-12-09 · Disposition to issuer · Disposed 4,739 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08	Direct	Reported balance After 2025-12-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-12-09 · Disposition to issuer · Disposed 3,527 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.09 · Expires 2029-12-13	Direct	Reported balance After 2025-12-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-12-09 · Disposition to issuer · Disposed 18,964 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16	Direct	Reported balance After 2025-12-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-12-09 · Disposition to issuer · Disposed 70,279 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08	Direct	Reported balance After 2025-12-09 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-12-09 · Disposition to issuer · Disposed 116,833 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.08 · Expires 2033-11-09	Direct	Reported balance After 2025-12-09 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-12-09 · Disposition to issuer · Disposed 83,400 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09	Direct	Reported balance After 2025-12-09 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-12-09 · Disposition to issuer · Disposed 84,051 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08	Direct	Reported balance After 2025-12-09 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-12-09 · Disposition to issuer · Disposed 82,482 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08	Direct	Reported balance After 2025-12-09 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2025-12-09 · Disposition to issuer · Disposed 29,074 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08	Direct	Reported balance After 2025-12-09 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2025-12-09 · Disposition to issuer · Disposed 29,074 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08	Direct	Reported balance After 2025-12-09 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2025-12-09 · Disposition to issuer · Disposed 29,073 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08	Direct	Reported balance After 2025-12-09 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2025-12-09 · Disposition to issuer · Disposed 74,053 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.09 · Expires 2029-12-13	Direct	Reported balance After 2025-12-09 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2025-12-09 · Disposition to issuer · Disposed 24,745 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").

F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.

Ventyx Biosciences, Inc.

Report date March 04, 2026 · Filed March 04, 2026

Section 16 reporting ended · disclosed 2026-03-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.29 · Expires 2034-06-06	Direct	Reported balance After 2026-03-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-04 · Disposition to issuer · Disposed 33,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-05	Direct	Reported balance After 2026-03-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-03-04 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2034-01-21	Direct	Reported balance After 2026-03-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-03-04 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.03 · Expires 2031-08-17	Direct	Reported balance After 2026-03-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-03-04 · Disposition to issuer · Disposed 119,120 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.54 · Expires 2032-06-09	Direct	Reported balance After 2026-03-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-03-04 · Disposition to issuer · Disposed 21,825 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.83 · Expires 2033-06-08	Direct	Reported balance After 2026-03-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-03-04 · Disposition to issuer · Disposed 15,937 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 29, 2022 Filed Jan 3, 2023 22:05 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $13.50	$0.00	Disclosure SEC source: 0000899243-23-000295 · doc4.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-12-28 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
December 28, 2022 Filed Dec 29, 2022 17:41 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	999	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0000899243-22-039531 · doc4.xml · derivative · entry 6 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,829 Underlying: Common Stock · 999 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
December 28, 2022 Filed Dec 29, 2022 17:41 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	999	$49.76	$49,713.74	Disclosure SEC source: 0000899243-22-039531 · doc4.xml · nonDerivative · entry 4 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,624 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $49.785, inclusive. Read SEC document
December 28, 2022 Filed Dec 29, 2022 17:41 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	999	$7.01	$7,001.99	Disclosure SEC source: 0000899243-22-039531 · doc4.xml · nonDerivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. Read SEC document
December 27, 2022 Filed Dec 29, 2022 17:41 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	19,001	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0000899243-22-039531 · doc4.xml · derivative · entry 5 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,828 Underlying: Common Stock · 19,001 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
December 27, 2022 Filed Dec 29, 2022 17:41 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	19,001	$49.77	$945,609.47	Disclosure SEC source: 0000899243-22-039531 · doc4.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,624 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $49.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document
December 27, 2022 Filed Dec 29, 2022 17:41 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	19,001	$7.01	$133,178.01	Disclosure SEC source: 0000899243-22-039531 · doc4.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. Read SEC document
December 16, 2022 Filed Dec 20, 2022 19:49 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantStock Option (Right to Buy) · Derivative	29,073	$0.00 Strike: $21.10	$0.00	Disclosure SEC source: 0000899243-22-039141 · doc4.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,221 Underlying: Common Stock · 29,073 shares Expires 2031-12-07 F1 · date: On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On December 16, 2022, the third performance milestone was achieved, resulting in the vesting of 29,073 shares underlying such option. F1 · derivative.exercise_date: On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On December 16, 2022, the third performance milestone was achieved, resulting in the vesting of 29,073 shares underlying such option. Read SEC document
December 09, 2022 Filed Dec 13, 2022 20:28 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantStock Option (Right to Buy) · Derivative	86,379	$0.00 Strike: $42.95	$0.00	Disclosure SEC source: 0000899243-22-038391 · doc4.xml · derivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,379 Underlying: Common Stock · 86,379 shares Expires 2032-12-08 F2 · derivative.exercise_date: This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document
December 09, 2022 Filed Dec 13, 2022 20:28 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantCommon Stock	19,195	$0.00	$0.00	Disclosure SEC source: 0000899243-22-038391 · doc4.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,624 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document
October 13, 2022 Filed Oct 17, 2022 17:40 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0000899243-22-033705 · doc4.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,829 Underlying: Common Stock · 20,000 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
October 13, 2022 Filed Oct 17, 2022 17:40 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	20,000	$39.82	$796,400.00	Disclosure SEC source: 0000899243-22-033705 · doc4.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.75 to $40.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document
October 13, 2022 Filed Oct 17, 2022 17:40 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	20,000	$7.01	$140,180.00	Disclosure SEC source: 0000899243-22-033705 · doc4.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. Read SEC document
September 13, 2022 Filed Sep 13, 2022 21:14 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantStock Option (Right to Buy) · Derivative	29,074	$0.00 Strike: $21.10	$0.00	Disclosure SEC source: 0001104659-22-099799 · tm2225839-3_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,148 Underlying: Common Stock · 29,074 shares Expires 2031-12-07 F3 · date: On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 13, 2022, the second performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option. F3 · derivative.exercise_date: On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 13, 2022, the second performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option. Read SEC document
September 13, 2022 Filed Sep 15, 2022 19:57 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	32,500	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0000899243-22-031198 · doc4.xml · derivative · entry 4 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,829 Underlying: Common Stock · 32,500 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
September 13, 2022 Filed Sep 15, 2022 19:57 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	13,580	$27.87	$378,474.60	Disclosure SEC source: 0000899243-22-031198 · doc4.xml · nonDerivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.24 to $28.09, inclusive. Read SEC document
September 13, 2022 Filed Sep 15, 2022 19:57 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	18,920	$26.42	$499,866.40	Disclosure SEC source: 0000899243-22-031198 · doc4.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,009 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.22 to $26.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document
September 13, 2022 Filed Sep 15, 2022 19:57 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	32,500	$7.01	$227,792.50	Disclosure SEC source: 0000899243-22-031198 · doc4.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person. Read SEC document
September 09, 2022 Filed Sep 13, 2022 21:14 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantStock Option (Right to Buy) · Derivative	29,074	$0.00 Strike: $21.10	$0.00	Disclosure SEC source: 0001104659-22-099799 · tm2225839-3_4seq1.xml · derivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,074 Underlying: Common Stock · 29,074 shares Expires 2031-12-07 F2 · date: On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 9, 2022, the first performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option. F2 · derivative.exercise_date: On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 9, 2022, the first performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option. Read SEC document
June 30, 2022 Filed Sep 13, 2022 21:14 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantCommon Stock	1,152	$8.03	$9,250.56	Disclosure SEC source: 0001104659-22-099799 · tm2225839-3_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429 F1 · shares: These shares were acquired on June 30, 2022 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 09, 2022 Filed Jun 10, 2022 21:41 UTC	Ventyx Biosciences, Inc. VTYX · Entity 62843	GrantStock Option (right to buy) · Derivative	13,301	$0.00 Strike: $16.54	$0.00	Disclosure SEC source: 0000899243-22-021983 · doc4.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,301 Underlying: Common Stock · 13,301 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document
June 09, 2022 Filed Apr 27, 2023 00:27 UTC Amendment	Ventyx Biosciences, Inc. VTYX · Entity 62843	GrantStock Option (right to buy) · Derivative	21,825	$0.00 Strike: $16.54	$0.00	Disclosure SEC source: 0000899243-23-011784 · doc4a.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,825 Underlying: Common Stock · 21,825 shares Expires 2032-06-09 F1 · shares: The Form 4 filed on June 10, 2022, erroneously reported that the reporting person received an option award for 13,301 shares on June 9, 2022. The correct option award amount is for 21,825 shares. F2 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date. F1 · derivative.underlying_shares: The Form 4 filed on June 10, 2022, erroneously reported that the reporting person received an option award for 13,301 shares on June 9, 2022. The correct option award amount is for 21,825 shares. F1 · balance_after: The Form 4 filed on June 10, 2022, erroneously reported that the reporting person received an option award for 13,301 shares on June 9, 2022. The correct option award amount is for 21,825 shares. Read SEC document
January 14, 2022 Filed Jan 18, 2022 21:48 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	9,700	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-22-005080 · tm223232-1_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,329 Underlying: Common Stock · 9,700 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
January 14, 2022 Filed Jan 18, 2022 21:48 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	9,700	$22.03	$213,691.00	Disclosure SEC source: 0001104659-22-005080 · tm223232-1_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $22.00 to $22.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
January 14, 2022 Filed Jan 18, 2022 21:48 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	9,700	$7.01	$67,987.30	Disclosure SEC source: 0001104659-22-005080 · tm223232-1_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 21, 2021 Filed Dec 23, 2021 21:03 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	100	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-21-153316 · tm2136193-1_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,029 Underlying: Common Stock · 100 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
December 21, 2021 Filed Dec 23, 2021 21:03 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	100	$22.00	$2,200.00	Disclosure SEC source: 0001104659-21-153316 · tm2136193-1_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person. Read SEC document
December 21, 2021 Filed Dec 23, 2021 21:03 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	100	$7.01	$700.90	Disclosure SEC source: 0001104659-21-153316 · tm2136193-1_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2021 Filed Dec 20, 2021 16:54 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	3,200	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-21-151760 · tm2135948-1_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,129 Underlying: Common Stock · 3,200 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
December 17, 2021 Filed Dec 20, 2021 16:54 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	3,200	$22.04	$70,528.00	Disclosure SEC source: 0001104659-21-151760 · tm2135948-1_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $22.00 to $22.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
December 17, 2021 Filed Dec 20, 2021 16:54 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	3,200	$7.01	$22,428.80	Disclosure SEC source: 0001104659-21-151760 · tm2135948-1_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 08, 2021 Filed Dec 10, 2021 17:08 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantStock Option (Right to Buy) · Derivative	87,221	$0.00 Strike: $21.10	$0.00	Disclosure SEC source: 0001104659-21-148675 · tm2135157-4_4seq.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,221 Underlying: Common Stock · 87,221 shares Expires 2031-12-07 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 equal monthly installments commencing on December 8, 2021. Read SEC document
November 01, 2021 Filed Nov 3, 2021 16:15 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	6,500	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-21-133649 · tm2131800-1_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,329 Underlying: Common Stock · 6,500 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
November 01, 2021 Filed Nov 3, 2021 16:15 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	6,500	$22.24	$144,560.00	Disclosure SEC source: 0001104659-21-133649 · tm2131800-1_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $22.05 to $22.46, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
November 01, 2021 Filed Nov 3, 2021 16:15 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	6,500	$7.01	$45,558.50	Disclosure SEC source: 0001104659-21-133649 · tm2131800-1_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 01, 2021 Filed Oct 5, 2021 16:10 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	6,500	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-21-123087 · tm2129283-1_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,829 Underlying: Common Stock · 6,500 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
October 01, 2021 Filed Oct 5, 2021 16:10 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	6,500	$22.06	$143,366.60	Disclosure SEC source: 0001104659-21-123087 · tm2129283-1_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $22.00 to $22.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
October 01, 2021 Filed Oct 5, 2021 16:10 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	6,500	$7.01	$45,558.50	Disclosure SEC source: 0001104659-21-123087 · tm2129283-1_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 01, 2021 Filed Sep 3, 2021 16:38 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	8,559	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-21-112969 · tm2126986-2_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,329 Underlying: Common Stock · 8,559 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
September 01, 2021 Filed Sep 3, 2021 16:38 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	8,559	$24.00	$205,416.00	Disclosure SEC source: 0001104659-21-112969 · tm2126986-2_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $23.65 to $24.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
September 01, 2021 Filed Sep 3, 2021 16:38 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	8,559	$7.01	$59,990.03	Disclosure SEC source: 0001104659-21-112969 · tm2126986-2_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 02, 2021 Filed Aug 4, 2021 17:39 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	4,441	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-21-100188 · tm2124177-1_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,888 Underlying: Common Stock · 4,441 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
August 02, 2021 Filed Aug 4, 2021 17:39 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	4,441	$22.03	$97,835.23	Disclosure SEC source: 0001104659-21-100188 · tm2124177-1_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $22.00 to $22.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
August 02, 2021 Filed Aug 4, 2021 17:39 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	4,441	$7.01	$31,126.97	Disclosure SEC source: 0001104659-21-100188 · tm2124177-1_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 06, 2021 Filed Jul 8, 2021 19:19 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	6,500	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-21-090367 · tm2121781-1_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,329 Underlying: Common Stock · 6,500 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
July 06, 2021 Filed Jul 8, 2021 19:19 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	6,500	$24.52	$159,380.00	Disclosure SEC source: 0001104659-21-090367 · tm2121781-1_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $24.12 to $24.80, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
July 06, 2021 Filed Jul 8, 2021 19:19 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	6,500	$7.01	$45,558.50	Disclosure SEC source: 0001104659-21-090367 · tm2121781-1_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 03, 2021 Filed May 4, 2021 16:06 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionStock Option (Right to Buy) · Derivative	4,200	$0.00 Strike: $7.01	$0.00	Disclosure SEC source: 0001104659-21-060965 · tm2115134-2_4seq1.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,829 Underlying: Common Stock · 4,200 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter. Read SEC document
May 03, 2021 Filed May 4, 2021 16:06 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	SaleCommon Stock	4,200	$30.56	$128,352.00	Disclosure SEC source: 0001104659-21-060965 · tm2115134-2_4seq1.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,270 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan dated October 5, 2020, as amended on November 18, 2020, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $30.30 to $30.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
May 03, 2021 Filed May 4, 2021 16:06 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	Exercise / conversionCommon Stock	4,200	$7.01	$29,437.80	Disclosure SEC source: 0001104659-21-060965 · tm2115134-2_4seq1.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.